Literature DB >> 2140373

Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring.

S H Preskorn1, G S Jerkovich.   

Abstract

Central nervous system (CNS) toxicity of tricyclic antidepressants (TCAs) is serious, costly, frequent, and difficult to diagnose early in its course. We first reviewed all published, systematic population studies of such CNS toxicity. Of 976 TCA-treated patients, 58 (6%) developed TCA-induced CNS toxicity. The risk of this toxicity was positively correlated with TCA plasma levels. For levels greater than 450 ng/ml, the risk increased more than 10-fold (to 67%). We further analyzed 36 cases in terms of phenomenology, course, and potential risk factors of TCA-induced toxicity. A protean prodrome involving affective, psychotic, and cognitive symptoms preceded the delirium, which on average took 2 weeks to develop. The variability of this prodrome often leads to erroneous clinical decisions. Risk factors for delirium, in order of importance, included TCA concentration in plasma, age, and female gender.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140373     DOI: 10.1097/00004714-199004000-00003

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  12 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 2.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

Review 3.  The safety of antidepressants.

Authors:  F de Jonghe; J A Swinkels
Journal:  Drugs       Date:  1992       Impact factor: 9.546

4.  Detection and quantification of tricyclic antidepressants and other psychoactive drugs in urine by HPLC/MS/MS for pain management compliance testing.

Authors:  Justin L Poklis; Carl E Wolf; Ashley Goldstein; M Lauren Wolfe; Alphonse Poklis
Journal:  J Clin Lab Anal       Date:  2012-07       Impact factor: 2.352

Review 5.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.

Authors:  M L Dahl; L Bertilsson; C Nordin
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

Review 7.  Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Authors:  Christoph Hiemke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 8.  Identifying patients at risk for, and treatment of major psychiatric complications of cancer.

Authors:  W Breitbart
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

Review 9.  Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications.

Authors:  L L von Moltke; D J Greenblatt; R I Shader
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

Review 10.  Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.

Authors:  Christoph Hiemke
Journal:  Eur J Clin Pharmacol       Date:  2008-01-15       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.